InVivoPlus recombinant CTLA-4-Ig (hum/hum)

Rochman Y, Yukawa M, Kartashov AV, et al. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS One. 2015,10(4):e0122198. doi: 10.1371/journal.pone.0122198

Schroder PM, Khattar M, Deng R, et al. Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice. PLoS One. 2013,8(7):e69397. doi: 10.1371/journal.pone.0069397

Chen Y, Shen S, Gorentla BK, et al. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol. 2012,188(4):1698-707. doi: 10.4049/jimmunol.1102448

Raedler H, Vieyra MB, Leisman S, et al. Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant. 2011,11(7):1397-406. doi: 10.1111/j.1600-6143.2011.03561.x

Whitlock EL, Myckatyn TM, Tong AY, et al. Dynamic quantification of host Schwann cell migration into peripheral nerve allografts. Exp Neurol. 2010,225(2):310-9. doi: 10.1016/j.expneurol.2010.07.001

Shen H, Goldstein DR. IL-6 and TNF-alpha synergistically inhibit allograft acceptance. J Am Soc Nephrol. 2009,20(5):1032-40. doi: 10.1681/ASN.2008070778